GlaxoSmithKline

     PHILADELPHIA – Blue Cross Blue Shield claims GlaxoSmithKline keeps its $1.3 billion annual monopoly on Wellbutrin SR (bupropion) through “fraudulent statements to patent examiners” and “filing baseless patent infringement actions” against generic manufacturers.